Login to Your Account


Salix buys into Ireland: Merger with Cosmo will lower taxes and expand GI pipeline

By Michael Fitzhugh
Staff Writer

Thursday, July 10, 2014
Salix Pharmaceuticals Ltd. is joining the tax inversion parade, with plans to beef up its gastrointestinal drug portfolio and trim its costs ahead of a planned supplemental new drug application for rifaximin and intentions to advance three new pipeline programs the merger delivers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription